Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2023-09-05 00:00:00 ET · period of report 2023-08-31 · accession 0001209191-23-048255 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-05 | 2023-09-05 | TVTX | Dube Eric M | CEO, Dir | S - Sale | $14.71 | -4,455 | 242.6K | -2% | -$65.5K | |
| 2023-09-05 | 2023-08-31 | TVTX | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +9,900 | 247.1K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-05 | S | D | 4,455 | $14.71 | 242,595 | D | — | — | |
| 2 | Common | Common Stock | 2023-08-31 | A | A | 9,900 | $0.00 | 247,050 | D | — | — |